三阴性乳腺癌:挑战、进展和有希望的治疗干预措施。

IF 3.5 4区 医学 Q2 ONCOLOGY
Deepanshi Sood, Charanjit Kaur, Naresh Kumar, Rajesh Kumar, Gurvinder Singh
{"title":"三阴性乳腺癌:挑战、进展和有希望的治疗干预措施。","authors":"Deepanshi Sood, Charanjit Kaur, Naresh Kumar, Rajesh Kumar, Gurvinder Singh","doi":"10.1007/s12032-025-03066-9","DOIUrl":null,"url":null,"abstract":"<p><p>Triple-Negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC), characterized by absence of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2). Approximately, 10-15% of BC patients are diagnosed with triple-negative breast cancer. In this review, we have summarized the approaches used for the treatment of triple-negative breast cancer. Due to the complex genetic makeup, Triple-Negative breast cancer has high potential for metastasis and is inherently difficult to treat and poses a grave threat. This review analyzes and provides insight into advancements in treatment methods and diagnostic techniques for TNBC. Schiff base compounds, capable of inducing apoptosis in malignant cells, are effective dual inhibitors of histone deacetylase type II and topoisomerase I. Detection strategies like advanced imaging techniques like core biopsy and automated breast ultrasound are important for enhancing TNBC diagnosis and treatment. The progress in developing combination therapies and improving drug delivery mechanisms has to be maintained in order to tackle the challenges in treatment. This work emphasizes the need for teamwork in the development of therapeutic approaches, which may offer new possibilities in the treatment of TNBC.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 11","pages":"506"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Triple-negative breast cancer: challenges, advances, and promising therapeutic interventions.\",\"authors\":\"Deepanshi Sood, Charanjit Kaur, Naresh Kumar, Rajesh Kumar, Gurvinder Singh\",\"doi\":\"10.1007/s12032-025-03066-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Triple-Negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC), characterized by absence of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2). Approximately, 10-15% of BC patients are diagnosed with triple-negative breast cancer. In this review, we have summarized the approaches used for the treatment of triple-negative breast cancer. Due to the complex genetic makeup, Triple-Negative breast cancer has high potential for metastasis and is inherently difficult to treat and poses a grave threat. This review analyzes and provides insight into advancements in treatment methods and diagnostic techniques for TNBC. Schiff base compounds, capable of inducing apoptosis in malignant cells, are effective dual inhibitors of histone deacetylase type II and topoisomerase I. Detection strategies like advanced imaging techniques like core biopsy and automated breast ultrasound are important for enhancing TNBC diagnosis and treatment. The progress in developing combination therapies and improving drug delivery mechanisms has to be maintained in order to tackle the challenges in treatment. This work emphasizes the need for teamwork in the development of therapeutic approaches, which may offer new possibilities in the treatment of TNBC.</p>\",\"PeriodicalId\":18433,\"journal\":{\"name\":\"Medical Oncology\",\"volume\":\"42 11\",\"pages\":\"506\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12032-025-03066-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-025-03066-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

三阴性乳腺癌(TNBC)是乳腺癌(BC)中最具侵袭性的亚型,其特征是缺乏雌激素、黄体酮和人表皮生长因子受体2 (HER2)。大约10-15%的BC患者被诊断为三阴性乳腺癌。在这篇综述中,我们总结了用于治疗三阴性乳腺癌的方法。由于复杂的基因组成,三阴性乳腺癌具有很高的转移潜力,并且具有固有的难以治疗和严重威胁。本文对TNBC的治疗方法和诊断技术的进展进行分析并提供见解。希夫碱化合物能够诱导恶性细胞凋亡,是有效的组蛋白去乙酰化酶II型和拓扑异构酶i的双重抑制剂。核心活检和自动乳腺超声等先进成像技术等检测策略对于提高TNBC的诊断和治疗非常重要。为了应对治疗方面的挑战,必须保持在开发联合疗法和改进给药机制方面的进展。这项工作强调了在治疗方法的发展中需要团队合作,这可能为TNBC的治疗提供新的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Triple-negative breast cancer: challenges, advances, and promising therapeutic interventions.

Triple-Negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC), characterized by absence of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2). Approximately, 10-15% of BC patients are diagnosed with triple-negative breast cancer. In this review, we have summarized the approaches used for the treatment of triple-negative breast cancer. Due to the complex genetic makeup, Triple-Negative breast cancer has high potential for metastasis and is inherently difficult to treat and poses a grave threat. This review analyzes and provides insight into advancements in treatment methods and diagnostic techniques for TNBC. Schiff base compounds, capable of inducing apoptosis in malignant cells, are effective dual inhibitors of histone deacetylase type II and topoisomerase I. Detection strategies like advanced imaging techniques like core biopsy and automated breast ultrasound are important for enhancing TNBC diagnosis and treatment. The progress in developing combination therapies and improving drug delivery mechanisms has to be maintained in order to tackle the challenges in treatment. This work emphasizes the need for teamwork in the development of therapeutic approaches, which may offer new possibilities in the treatment of TNBC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Oncology
Medical Oncology 医学-肿瘤学
CiteScore
4.20
自引率
2.90%
发文量
259
审稿时长
1.4 months
期刊介绍: Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信